RINCON, Puerto Rico, May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ:AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya. On May 20, 20

MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") relat

Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ:AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. With the amended exchange ratio, Quanterix will issue over 9 million fewer

MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and molecular data, today announced a groundbreaking collaboration to deliver the largest commercially available single-cell spatial proteomics atlas to the research and clinical community. Enable Medicine's Pan-Cancer Atlas is a unique multi-modal dataset built using Akoya's PhenoCycler®-Fusion (PCF) platform and includes the PhenoCode™ Discovery IO60 panel as its foundational data. The Enable Atlas comprises over 100 million single cells, spanning 8,500+ samples and 15+ cancer typ

MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibody-drug conjugate (ADC) development in breast cancer. The new assay will be featured alongside customer-generated real-world data from the PhenoCode™ Discovery IO60 panel—Akoya's flagship ultrahigh-plex immuno-oncology solution—at the American Association for Cancer Research (AACR) 2025 Annual Meeting, taking place April 25–30 in Chicago, Illinois. New ADC Assay: Advancing Breast Cancer Precision The emergence of HER2- and TROP2-targeting ADCs—such as those used in the DESTINY, ASCENT, and TRO

The STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of identifying predictors of PD1 immunotherapy response in an Asian real-world setting, bringing together Singapore's public healthcare and research institutions in the translational cancer research ecosystem, comprising the National Cancer Centre Singapore (NCCS), National University Cancer Institute, Singapore (NCIS), National University Hospital (NUH), National University of Singapore (NUS), Singapore General Hospital (SGH) and the Agency for Science, Technology and Research (A*STAR). The partnership between Akoya Biosciences and STCC will leverage Akoya Biosciences' Phe

Urges Shareholders to Vote AGAINST Both Proposals Related to the Value-Destructive Merger with Akoya at the Upcoming Special Meeting Notes Deeply Unfair Merger is Effectively a Bailout for Akoya at the Expense of Quanterix Shareholders Outlines Concerns Around Fundamentally Flawed Transaction Process and Conflicts of Interest Among Quanterix Board Members Visit www.SaveQTRX.com to Learn How to Vote the GOLD Proxy Card and Preserve Quanterix's Clear and Compelling Path Toward Long-Term Value Creation Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today announced that it

Tikvah Management LLC (together with its affiliates, "Tikvah" or "we"), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued a statement calling on the Company to explain its most recent purchase agreement for up to $30 million in convertible notes from Akoya Biosciences, Inc. ("Akoya") (NASDAQ:AKYA). Tikvah's statement follows: "This announcement concerns us for several reasons. First, we believe Akoya's need to obtain bridge financing serves as a significant warning sign of its financial distress. Second, we find it both unusual and coercive to Quanterix's shareholders that this capital is being comm

Disturbed that Quanterix Is Apparently Moving Forward with One of the Most Shareholder Unfriendly Aspects of Merger Agreement with Akoya Encourages Shareholders to Vote AGAINST Both Proposals Related to Approval of the Transaction Kent Lake PR LLC ("Kent Lake") is a holder of approximately 7.5% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX). Today, Kent Lake issued a statement related to recent disclosures indicating that Quanterix has officially entered into a Securities Purchase Agreement under which Akoya Biosciences ("Akoya") (NASDAQ:AKYA) has the ability to sell the Company up to $30 million in convertible notes. Kent Lake has p